他莫昔芬与氨鲁米特及他莫昔芬联合氨鲁米特治疗绝经后晚期乳腺癌的随机试验
Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer.
作者信息
Alonso-Muñoz M C, Ojeda-González M B, Beltran-Fabregat M, Dorca-Ribugent J, López-López L, Borrás-Balada J, Cardenal-Alemany F, Gómez-Batiste X, Fabregat-Mayol J, Viladiu-Quemada P
机构信息
Hospital de la Santa Creu i Sant Pau, Barcelona.
出版信息
Oncology. 1988;45(5):350-3. doi: 10.1159/000226639.
In a randomized trial, 105 postmenopausal women with advanced carcinoma of the breast received tamoxifen or aminoglutethimide or combined tamoxifen and aminoglutethimide. No differences were found in the rate of responses and duration of responses between the treatment groups. Toxicity was significantly greater (p less than 0.01) in patients who received aminoglutethimide.
在一项随机试验中，105名绝经后晚期乳腺癌妇女接受了他莫昔芬、氨鲁米特或他莫昔芬与氨鲁米特联合治疗。各治疗组之间在缓解率和缓解持续时间方面未发现差异。接受氨鲁米特治疗的患者毒性显著更大（p<0.01）。
Zotero 插件